|
|
|
EKR Therapeutics Acquires
Cedar Knolls, NJ, October 12, 2006
- EKR Therapeutics, Inc. has signed an agreement to acquire
exclusive North American license and distribution rights for
Gelclair® from Helsinn Healthcare SA, a privately owned
pharmaceutical company headquartered in Switzerland. Gelclair® is
the product specifically designed and approved by the FDA for the
management of pain associated with oral mucositis / stomatitis.
“This is a significant milestone for EKR”, commented Howard Weisman,
Chairman & CEO. “Gelclair® is the first of several planned product
acquisitions in the area of oncology supportive care. These types of
products are becoming an increasingly essential part of the total
care of cancer patients as they help to improve the quality of life
while undergoing aggressive treatments in a variety of tumor types.”
Gelclair is a bio-adherent oral gel with a mechanical action
indicated for the management of pain and relief of pain by adhering
to the mucosal surface of the mouth, soothing oral lesions of
various etiologies, including oral mucostis/stomatitis which may be
caused by chemotherapy or radiation therapy. Oral mucositis has been
reported in 15-40% of patients receiving stomatoxic chemotherapy or
radiotherapy, 70-90% of stem cell transplant recipients, and 100% of
patients receiving head and neck radiotherapy (doses >5000 cGy).
Severe oral mucositis may result in a reduction in the dose of
chemotherapy or a delay in treatment.
|
|
|
